Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab dose reduction in ankylosing spondylitis with low disease activity (Chinese real-world cohort)
ChiCTR2300072687Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Chengdu Medical College
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab in ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA) (2 arms), sponsored by The First Affiliated Hospital of Chengdu Medical College. Primary endpoint: Proportion of patients with low disease activity. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
03
Conditions
ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on ChiCTR2300072687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072687.